<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene K417N,E484K,N501Y literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.[K417N;E484K;N501Y]</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.<br/> (<a href="https://doi.org/10.1101/2021.02.16.431305" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).<br/> (<a href="https://doi.org/10.1101/2021.02.14.431117" class="lit_link">Tian et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> The affinity of ACE2 for this mutation combination was twice as high as for wild type.<br/>Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.<br/> (<a href="https://doi.org/10.1101/2021.03.04.433887" class="lit_link">Vogel et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.<br/> (<a href="https://doi.org/10.1101/2021.02.22.432357" class="lit_link">Laffeber et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).<br/> (<a href="https://doi.org/10.1101/2021.02.22.432359" class="lit_link">Ramanathan et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30 (<a href="https://doi.org/10.1038/s41586-021-03412-7" class="lit_link">Collier et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> 27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 "South African" lineage), while only 23% retained high titres  (<a href="https://doi.org/10.1101/2021.01.18.427166" class="lit_link">Wibmer et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.<br/> (<a href="https://doi.org/10.1101/2021.02.16.431305" class="lit_link">Liu et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.<br/> (<a href="https://doi.org/10.1101/2021.04.27.440939" class="lit_link">Engelhart et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
